vs
Side-by-side financial comparison of EDGEWELL PERSONAL CARE Co (EPC) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.
QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $422.8M, roughly 1.5× EDGEWELL PERSONAL CARE Co). QuidelOrtho Corp runs the higher net margin — -14.8% vs -15.5%, a 0.7% gap on every dollar of revenue. On growth, QuidelOrtho Corp posted the faster year-over-year revenue change (-10.5% vs -11.6%). Over the past eight quarters, QuidelOrtho Corp's revenue compounded faster (-6.6% CAGR vs -16.0%).
The Edgewell Personal Care Company is an American multinational consumer products company headquartered in Shelton, Connecticut. It was formed in 2015 following the corporate spin-off from Energizer Holdings, Inc..
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
EPC vs QDEL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2027
| Metric | | |
|---|---|---|
| Revenue | $422.8M | $619.8M |
| Net Profit | $-65.7M | $-91.8M |
| Gross Margin | 38.1% | — |
| Operating Margin | -4.5% | — |
| Net Margin | -15.5% | -14.8% |
| Revenue YoY | -11.6% | -10.5% |
| Net Profit YoY | -3028.6% | — |
| EPS (diluted) | $-1.41 | $-1.35 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $619.8M | ||
| Q4 25 | $422.8M | — | ||
| Q3 25 | $600.5M | $699.9M | ||
| Q2 25 | $627.2M | $613.9M | ||
| Q1 25 | $580.7M | $692.8M | ||
| Q4 24 | $415.1M | $707.8M | ||
| Q3 24 | $517.6M | $727.1M | ||
| Q2 24 | $647.8M | $637.0M |
| Q1 26 | — | $-91.8M | ||
| Q4 25 | $-65.7M | — | ||
| Q3 25 | $-30.6M | $-733.0M | ||
| Q2 25 | $29.1M | $-255.4M | ||
| Q1 25 | $29.0M | $-12.7M | ||
| Q4 24 | $-2.1M | $-178.4M | ||
| Q3 24 | $8.8M | $-19.9M | ||
| Q2 24 | $49.0M | $-147.7M |
| Q1 26 | — | — | ||
| Q4 25 | 38.1% | — | ||
| Q3 25 | 37.9% | — | ||
| Q2 25 | 42.8% | — | ||
| Q1 25 | 44.1% | — | ||
| Q4 24 | 41.6% | — | ||
| Q3 24 | 41.1% | — | ||
| Q2 24 | 44.3% | — |
| Q1 26 | — | — | ||
| Q4 25 | -4.5% | — | ||
| Q3 25 | -4.2% | -100.7% | ||
| Q2 25 | 8.6% | -29.4% | ||
| Q1 25 | 10.1% | 4.7% | ||
| Q4 24 | 2.2% | -14.2% | ||
| Q3 24 | 3.9% | 2.1% | ||
| Q2 24 | 12.8% | -18.4% |
| Q1 26 | — | -14.8% | ||
| Q4 25 | -15.5% | — | ||
| Q3 25 | -5.1% | -104.7% | ||
| Q2 25 | 4.6% | -41.6% | ||
| Q1 25 | 5.0% | -1.8% | ||
| Q4 24 | -0.5% | -25.2% | ||
| Q3 24 | 1.7% | -2.7% | ||
| Q2 24 | 7.6% | -23.2% |
| Q1 26 | — | $-1.35 | ||
| Q4 25 | $-1.41 | — | ||
| Q3 25 | $-0.65 | $-10.78 | ||
| Q2 25 | $0.62 | $-3.77 | ||
| Q1 25 | $0.60 | $-0.19 | ||
| Q4 24 | $-0.04 | $-2.54 | ||
| Q3 24 | $0.18 | $-0.30 | ||
| Q2 24 | $0.98 | $-2.20 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $140.4M |
| Total DebtLower is stronger | $1.5B | $2.5B |
| Stockholders' EquityBook value | $1.5B | $1.9B |
| Total Assets | $3.8B | $5.6B |
| Debt / EquityLower = less leverage | 1.03× | 1.33× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $140.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $98.1M | ||
| Q2 25 | — | $151.7M | ||
| Q1 25 | — | $127.1M | ||
| Q4 24 | — | $98.3M | ||
| Q3 24 | $209.1M | $143.7M | ||
| Q2 24 | — | $107.0M |
| Q1 26 | — | $2.5B | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.4B | $2.5B | ||
| Q2 25 | $1.4B | $2.1B | ||
| Q1 25 | $1.4B | $2.1B | ||
| Q4 24 | $1.4B | $2.1B | ||
| Q3 24 | $1.3B | $2.2B | ||
| Q2 24 | $1.3B | $2.2B |
| Q1 26 | — | $1.9B | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.6B | $2.0B | ||
| Q2 25 | $1.6B | $2.8B | ||
| Q1 25 | $1.5B | $3.0B | ||
| Q4 24 | $1.5B | $3.0B | ||
| Q3 24 | $1.6B | $3.2B | ||
| Q2 24 | $1.6B | $3.2B |
| Q1 26 | — | $5.6B | ||
| Q4 25 | $3.8B | — | ||
| Q3 25 | $3.8B | $5.7B | ||
| Q2 25 | $3.8B | $6.4B | ||
| Q1 25 | $3.8B | $6.5B | ||
| Q4 24 | $3.7B | $6.4B | ||
| Q3 24 | $3.7B | $6.8B | ||
| Q2 24 | $3.7B | $6.7B |
| Q1 26 | — | 1.33× | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 0.89× | 1.23× | ||
| Q2 25 | 0.88× | 0.74× | ||
| Q1 25 | 0.95× | 0.70× | ||
| Q4 24 | 0.97× | 0.72× | ||
| Q3 24 | 0.81× | 0.68× | ||
| Q2 24 | 0.82× | 0.70× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-125.9M | — |
| Free Cash FlowOCF − Capex | $-137.5M | — |
| FCF MarginFCF / Revenue | -32.5% | — |
| Capex IntensityCapex / Revenue | 2.7% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $36.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-125.9M | — | ||
| Q3 25 | $74.1M | $-45.5M | ||
| Q2 25 | $114.8M | $-46.8M | ||
| Q1 25 | $45.1M | $65.6M | ||
| Q4 24 | $-115.6M | $63.7M | ||
| Q3 24 | $-388.3M | $117.9M | ||
| Q2 24 | $101.2M | $-97.9M |
| Q1 26 | — | — | ||
| Q4 25 | $-137.5M | — | ||
| Q3 25 | $46.5M | $-94.7M | ||
| Q2 25 | $99.3M | $-84.3M | ||
| Q1 25 | $28.0M | $9.4M | ||
| Q4 24 | $-132.4M | $16.5M | ||
| Q3 24 | $-414.2M | $71.4M | ||
| Q2 24 | $88.6M | $-133.2M |
| Q1 26 | — | — | ||
| Q4 25 | -32.5% | — | ||
| Q3 25 | 7.7% | -13.5% | ||
| Q2 25 | 15.8% | -13.7% | ||
| Q1 25 | 4.8% | 1.4% | ||
| Q4 24 | -31.9% | 2.3% | ||
| Q3 24 | -80.0% | 9.8% | ||
| Q2 24 | 13.7% | -20.9% |
| Q1 26 | — | — | ||
| Q4 25 | 2.7% | — | ||
| Q3 25 | 4.6% | 7.0% | ||
| Q2 25 | 2.5% | 6.1% | ||
| Q1 25 | 2.9% | 8.1% | ||
| Q4 24 | 4.0% | 6.7% | ||
| Q3 24 | 5.0% | 6.4% | ||
| Q2 24 | 1.9% | 5.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.95× | — | ||
| Q1 25 | 1.56× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -44.13× | — | ||
| Q2 24 | 2.07× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EPC
| Other | $242.0M | 57% |
| Sunand Skin Care Segment | $131.5M | 31% |
| Shavinggelsandcreams | $32.3M | 8% |
| Wipes And Other Skin Care Products | $17.0M | 4% |
QDEL
| Labs | $353.1M | 57% |
| Immunohematology | $138.3M | 22% |
| Point of Care | $112.8M | 18% |
| Molecular Diagnostics | $7.8M | 1% |
